Glaxosmithkline Plc Adr Stock Analysis
| GSK Stock | USD 39.27 0.33 0.83% |
GlaxoSmithKline PLC ADR is fairly valued with Real Value of 39.89 and Target Price of 39.63. The main objective of GlaxoSmithKline PLC stock analysis is to determine its intrinsic value, which is an estimate of what GlaxoSmithKline PLC ADR is worth, separate from its market price. There are two main types of GlaxoSmithKline PLC's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect GlaxoSmithKline PLC's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of GlaxoSmithKline PLC's stock to identify patterns and trends that may indicate its future price movements.
The GlaxoSmithKline PLC stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. GlaxoSmithKline PLC is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. GlaxoSmithKline Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and GlaxoSmithKline PLC's ongoing operational relationships across important fundamental and technical indicators.
GlaxoSmithKline |
GlaxoSmithKline Stock Analysis Notes
About 14.0% of the company shares are owned by institutional investors. The book value of GlaxoSmithKline PLC was currently reported as 3.29. The company has Price/Earnings To Growth (PEG) ratio of 1.09. GlaxoSmithKline PLC ADR last dividend was issued on the 22nd of February 2024. The entity had 1226:1000 split on the 22nd of July 2022. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Gsk Plc is traded on New York Stock Exchange in the United States. To learn more about GlaxoSmithKline PLC ADR call Emma Walmsley at 44 20 8047 5000 or check out https://www.gsk.com.GlaxoSmithKline PLC Quarterly Total Revenue |
|
GlaxoSmithKline PLC ADR Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. GlaxoSmithKline PLC's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding GlaxoSmithKline PLC ADR or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| GlaxoSmithKline PLC has a strong financial position based on the latest SEC filings | |
| On 11th of April 2024 GlaxoSmithKline PLC paid $ 0.4061 per share dividend to its current shareholders | |
| Latest headline from benzinga.com: Once Valued At Billions, 23andMes CEO Considers Privatization To Secure Companys Future |
GlaxoSmithKline PLC ADR Upcoming and Recent Events
Earnings reports are used by GlaxoSmithKline PLC to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to GlaxoSmithKline PLC previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 31st of January 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 31st of January 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
GlaxoSmithKline Largest EPS Surprises
Earnings surprises can significantly impact GlaxoSmithKline PLC's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-07-29 | 2020-06-30 | 0.64 | 0.57 | -0.07 | 10 | ||
2016-02-03 | 2015-12-31 | 0.61 | 0.69 | 0.08 | 13 | ||
1995-02-07 | 1994-12-31 | 0.9 | 0.99 | 0.09 | 10 |
GlaxoSmithKline PLC Thematic Classifications
In addition to having GlaxoSmithKline PLC stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | HealthcareUSA Equities from Healthcare industry as classified by Fama & French |
GlaxoSmithKline Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as GlaxoSmithKline PLC is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GlaxoSmithKline PLC ADR backward and forwards among themselves. GlaxoSmithKline PLC's institutional investor refers to the entity that pools money to purchase GlaxoSmithKline PLC's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Arrowstreet Capital Limited Partnership | 2023-12-31 | 4.8 M | Mondrian Investment Partners Ltd | 2023-12-31 | 4 M | Provident Trust Company | 2023-12-31 | 3.7 M | Equity Investment Corp | 2023-12-31 | 3.2 M | Eversept Partners, Llc | 2023-12-31 | 3 M | Renaissance Technologies Corp | 2023-12-31 | 2.8 M | Hotchkis & Wiley Capital Management Llc | 2023-12-31 | 2.7 M | Hsbc Holdings Plc | 2023-12-31 | 2.5 M | Wells Fargo & Co | 2023-12-31 | 2.5 M | Dodge & Cox | 2023-12-31 | 69 M | Fmr Inc | 2023-12-31 | 19.4 M |
GlaxoSmithKline Market Capitalization
The company currently falls under 'Large-Cap' category with a total capitalization of 81.18 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate GlaxoSmithKline PLC's market, we take the total number of its shares issued and multiply it by GlaxoSmithKline PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.GlaxoSmithKline Profitablity
GlaxoSmithKline PLC's profitability indicators refer to fundamental financial ratios that showcase GlaxoSmithKline PLC's ability to generate income relative to its revenue or operating costs. If, let's say, GlaxoSmithKline PLC is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, GlaxoSmithKline PLC's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of GlaxoSmithKline PLC's profitability requires more research than a typical breakdown of GlaxoSmithKline PLC's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin of 0.16 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.2 %, which entails that for every 100 dollars of revenue, it generated $0.2 of operating income. | Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.13 | 0.21 | |
| Return On Capital Employed | 0.18 | 0.18 | |
| Return On Assets | 0.08 | 0.15 | |
| Return On Equity | 0.37 | 0.42 |
Management Efficiency
GlaxoSmithKline PLC ADR has Return on Asset of 0.0881 % which means that on every $100 spent on assets, it made $0.0881 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4638 %, implying that it generated $0.4638 on every 100 dollars invested. GlaxoSmithKline PLC's management efficiency ratios could be used to measure how well GlaxoSmithKline PLC manages its routine affairs as well as how well it operates its assets and liabilities. At this time, GlaxoSmithKline PLC's Return On Tangible Assets are quite stable compared to the past year. Return On Assets is expected to rise to 0.15 this year, although the value of Return On Capital Employed will most likely fall to 0.18. Change To Liabilities is expected to rise to about 596.5 M this year, although the value of Total Current Liabilities will most likely fall to about 11.2 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.29 | 2.26 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | (2.17) | (2.06) | |
| Enterprise Value Over EBITDA | 14.34 | 7.90 | |
| Price Book Value Ratio | 8.85 | 9.29 | |
| Enterprise Value Multiple | 14.34 | 7.90 | |
| Price Fair Value | 8.85 | 9.29 | |
| Enterprise Value | 133.2 B | 139.8 B |
The analysis of GlaxoSmithKline PLC's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze GlaxoSmithKline PLC's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of GlaxoSmithKline Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Dividend Yield 0.037 | Forward Dividend Yield 0.037 | Forward Dividend Rate 1.47 | Beta 0.268 |
Technical Drivers
As of the 19th of April, GlaxoSmithKline PLC retains the risk adjusted performance of 4.0E-4, and Market Risk Adjusted Performance of (0.02). GlaxoSmithKline PLC technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We are able to interpolate and collect thirteen technical drivers for GlaxoSmithKline PLC ADR, which can be compared to its competitors. Please check out GlaxoSmithKline PLC ADR risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if GlaxoSmithKline PLC is priced fairly, providing market reflects its last-minute price of 39.27 per share. Given that GlaxoSmithKline PLC ADR has information ratio of (0.08), we strongly advise you to confirm GlaxoSmithKline PLC ADR's regular market performance to make sure the company can sustain itself at a future point.GlaxoSmithKline PLC ADR Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. GlaxoSmithKline PLC middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for GlaxoSmithKline PLC ADR. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
GlaxoSmithKline PLC Predictive Daily Indicators
GlaxoSmithKline PLC intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of GlaxoSmithKline PLC stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
GlaxoSmithKline PLC Corporate Filings
6K | 17th of April 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 16th of April 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 15th of April 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 4th of April 2024 Other Reports | ViewVerify | |
6K | 2nd of April 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
F3 | 28th of March 2024 An amendment to the original Schedule 13D filing | ViewVerify |
6K | 26th of March 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 25th of March 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
GlaxoSmithKline PLC Forecast Models
GlaxoSmithKline PLC's time-series forecasting models are one of many GlaxoSmithKline PLC's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary GlaxoSmithKline PLC's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About GlaxoSmithKline Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how GlaxoSmithKline PLC prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling GlaxoSmithKline shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as GlaxoSmithKline PLC. By using and applying GlaxoSmithKline Stock analysis, traders can create a robust methodology for identifying GlaxoSmithKline entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | 0.20 | 0.31 | |
| Operating Profit Margin | 0.23 | 0.32 | |
| Net Profit Margin | 0.16 | 0.22 | |
| Gross Profit Margin | 0.70 | 0.78 |
Current GlaxoSmithKline Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. GlaxoSmithKline analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. GlaxoSmithKline analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 39.63 | Buy | 8 | Odds |
Most GlaxoSmithKline analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand GlaxoSmithKline stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of GlaxoSmithKline PLC ADR, talking to its executives and customers, or listening to GlaxoSmithKline conference calls.
GlaxoSmithKline Stock Analysis Indicators
GlaxoSmithKline PLC ADR stock analysis indicators help investors evaluate how GlaxoSmithKline PLC stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading GlaxoSmithKline PLC shares will generate the highest return on investment. By understating and applying GlaxoSmithKline PLC stock analysis, traders can identify GlaxoSmithKline PLC position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 3.7 B | |
| Long Term Debt | 14.2 B | |
| Common Stock Shares Outstanding | 4.1 B | |
| Total Stockholder Equity | 13.3 B | |
| Total Cashflows From Investing Activities | -1.6 B | |
| Tax Provision | 756 M | |
| Quarterly Earnings Growth Y O Y | -0.766 | |
| Property Plant And Equipment Net | 10 B | |
| Cash And Short Term Investments | 5.2 B | |
| Cash | 2.9 B | |
| Accounts Payable | 3.7 B | |
| Net Debt | 15.1 B | |
| 50 Day M A | 41.9664 | |
| Total Current Liabilities | 21.1 B | |
| Other Operating Expenses | 23.3 B | |
| Non Current Assets Total | 40.4 B | |
| Forward Price Earnings | 10.3199 | |
| Non Currrent Assets Other | 634 M | |
| Stock Based Compensation | 307 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Dividend Share 0.58 | Earnings Share 2.99 | Revenue Per Share 14.97 | Quarterly Revenue Growth 0.092 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.